Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy

被引:50
作者
Belluardo, Paola
Cataliotti, Alessandro
Bonaiuto, Lorena
Giuffre, Eliana
Maugeri, Egle
Noto, Paola
Orlando, Giovanna
Raspa, Giuseppa
Piazza, Brigida
Babuin, Luciano
Chen, Horng H.
Martin, Fernando L.
McKie, Paul M.
Heublein, Denise M.
Burnett, John C., Jr.
Malatino, Lorenzo S.
机构
[1] Mayo Clin Rochester, Cardiorenal Res Lab, Rochester, MN 55905 USA
[2] Univ Catania, Dept Med, Catania, Italy
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2006年 / 291卷 / 04期
关键词
natriuretic peptide; brain natriuretic peptide; amino-terminal pro-brain natriuretic peptide; left ventricular hypertrophy;
D O I
10.1152/ajpheart.00107.2006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated relationships among two circulating molecular forms of brain natriuretic peptide (BNP32 and NT-proBNP), severity of hypertension (HTN), and cardiac hypertrophy in subjects with mild, moderate, and severe HTN. We prospectively studied 78 patients (43 males; mean age 51.4 +/- 11 yr) with essential HTN and 28 age- and sex-matched controls. BNP32 and NT-proBNP were measured by radioimmunoassay. In grade 1 HTN, BNP32 was not elevated and NT-proBNP was reduced ( P = 0.030) compared with controls. However, log-transformed values of BNP32 and NT-proBNP were both increased with severity of HTN from grade 1 to 3 (P < 0.0001 and P = 0.003, respectively). By multivariate analysis, log BNP32 was independently predicted by age (beta = 0.210, P = 0.026) and HTN grade (beta = 0.274, P = 0.004), whereas log NT-proBNP was independently predicted by sex (beta = 0.235, P = 0.012) and HTN grade (beta = 0.218, P = 0.0023). Two forms of BNP were measured in normal subjects and patients with essential HTN. In grade 1 HTN, BNP32 was unchanged and NT-proBNP was significantly reduced compared with controls. As severity increased in humans with grade 1 to 3 HTN, both BNP32 and NT-proBNP levels were increased while not being affected by the presence of left ventricular hypertrophy. The lack of activation of BNP32 together with the reduction of NT-proBNP in grade 1 HTN may represent an impaired response of the BNP system in the early phase of HTN. The later activation of both forms of BNP may be a late compensatory effect, because it correlates with severity of HTN rather than cardiac hypertrophy/remodeling.
引用
收藏
页码:H1529 / H1535
页数:7
相关论文
共 40 条
  • [1] Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1
  • [2] Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides
    Ala-Kopsala, M
    Magga, J
    Peuhkurinen, K
    Leipälä, J
    Ruskoaho, H
    Leppäluoto, J
    Vuolteenaho, A
    [J]. CLINICAL CHEMISTRY, 2004, 50 (09) : 1576 - 1588
  • [3] BERKOWITZ B, 2004, REV CARDIOVASC ME S4, V5, pS3
  • [4] BIOSYNTHESIS AND SECRETION OF PROATRIAL NATRIURETIC FACTOR BY CULTURED RAT CARDIOCYTES
    BLOCH, KD
    SCOTT, JA
    ZISFEIN, JB
    FALLON, JT
    MARGOLIES, MN
    SEIDMAN, CE
    MATSUEDA, GR
    HOMCY, CJ
    GRAHAM, RM
    SEIDMAN, JG
    [J]. SCIENCE, 1985, 230 (4730) : 1168 - 1171
  • [5] Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
    Brunner-La Rocca, HP
    Kaye, DM
    Woods, RL
    Hastings, J
    Esler, MD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1221 - 1227
  • [6] BUCKLEY MG, 1993, J HUM HYPERTENS, V7, P245
  • [7] ATRIAL-NATRIURETIC-PEPTIDE ELEVATION IN CONGESTIVE-HEART-FAILURE IN THE HUMAN
    BURNETT, JC
    KAO, PC
    HU, DC
    HESER, DW
    HEUBLEIN, D
    GRANGER, JP
    OPGENORTH, TJ
    REEDER, GS
    [J]. SCIENCE, 1986, 231 (4742) : 1145 - 1147
  • [8] Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure
    Cataliotti, A
    Schirger, JA
    Martin, FL
    Chen, HNH
    McKie, PM
    Boerrigter, G
    Costello-Boerrigter, LC
    Harty, G
    Heublein, DM
    Sandberg, SM
    James, KD
    Miller, MA
    Malkar, NB
    Polowy, K
    Burnett, JC
    [J]. CIRCULATION, 2005, 112 (06) : 836 - 840
  • [9] Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure
    Cataliotti, A
    Boerrigter, G
    Costello-Boerrigter, LC
    Schirger, JA
    Tsuruda, T
    Heublein, DM
    Chen, HH
    Malatino, LS
    Burnett, JC
    [J]. CIRCULATION, 2004, 109 (13) : 1680 - 1685
  • [10] Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling
    Cataliotti, A
    Malatino, LS
    Jougasaki, M
    Zoccali, C
    Castellino, P
    Giacone, G
    Bellanuova, I
    Tripepi, R
    Seminara, G
    Parlongo, S
    Stancanelli, B
    Bonanno, G
    Fatuzzo, P
    Rapisarda, F
    Belluardo, P
    Signorelli, SS
    Heublein, DM
    Lainchbury, JG
    Leskinen, HK
    Bailey, KR
    Redfield, MM
    Burnett, JC
    [J]. MAYO CLINIC PROCEEDINGS, 2001, 76 (11) : 1111 - 1119